Vidac Pharma Holding PLC
by Sandra Gamzon
Business news for the stock market London (pta/04.10.2026/10:35) - Shareholders approved the reappointment of Dr. Max Herzberg, Mr. Yochai Richter, Dr. Christian Policard and Mr. Joseph Tenne as directors. The meeting received the Company's annual report and audited consolidated financial statements for the year ended 31 December 2025, together with the directors' and auditor's reports. MHA Audit Services LLP was reappointed as the Company's auditor until the conclusion of the next accounts meeting, and the directors were authorised to determine its remuneration. Shareholders also approved the Company's strategy to partner with Eutopos Pharma, a French company intended to undertake fundraising, development and commercialisation activities initially in Europe, with the final territory to be agreed. This approval relates to the Company's strategy and does not constitute an announcement that a definitive licence agreement has been executed. The meeting renewed the directors' authority to allot shares and grant subscription or conversion rights up to an aggregate nominal amount of £10,694,620. Shareholders also passed special resolutions approving the disapplication of statutory pre-emption rights within the limits specified in the AGM notice and authorising the capitalisation of up to £5,000,000 from the specified reserves to pay up shares issued under the approved authorities. The allotment authority and associated pre-emption disapplication expire at the conclusion of the next Annual General Meeting or 15 months after their approval, whichever is earlier, subject to the provisions for offers and agreements entered into before expiry. The Board provided an update on recent developments and business plans and addressed shareholder questions concerning the Company's prospective expansion in Europe. The full terms of the resolutions are set out in the Notice of Annual General Meeting dated 8 September 2026. Enquiries: Nataliia Kronik Company Secretary kronik@companiessecretary.com About Vidac Pharma Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases. The Company develops therapeutic candidates designed to modify the hyper-glycolytic tumor microenvironment by targeting the overexpression and mislocalization of the Hexokinase-2 (HK2) metabolic checkpoint in cancer cells, with the aim of renormalizing cellular metabolism and selectively inducing programmed cell death without affecting surrounding normal tissue. Vidac's lead drug candidate, VDA-1102, has previously demonstrated activity in clinical studies in Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL). Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, among others, statements relating to the Company's business strategy, prospective expansion in Europe, potential partnership arrangements, fundraising, development and commercialisation activities, and future corporate and operational plans. Forward-looking statements are based on current expectations, assumptions, and information available to the Company at the time of publication and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, the execution of definitive agreements, financing availability, regulatory developments, market conditions, clinical development outcomes and execution risks. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law. (end) emitter: Vidac Pharma Holding PLC address: 20-22 Wenlock Road, N1 7GU London country: United Kingdom contact person: Sandra Gamzon phone: +972 544 999951 e-mail: investors@vidacpharma.com website: www.vidacpharma.com ISIN(s): GB00BM9XQ619 (share) stock exchanges: Primärmarkt in Dusseldorf, free market in Hamburg, free market in Stuttgart other stock exchanges: XETRA pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext.adhoc. Archive: http://adhoc.pressetext.com The emitter is responsible for the content. Contact: adhoc@pressetext.com or +43-1-81140-0.
